Background
Monsanto Company holds patents on the Roundup Ready genetic trait — a modification that makes soybean and cotton plants resistant to glyphosate herbicides. Monsanto licenses this technology through authorized seed companies, and every bag sold comes with a Technology Agreement prohibiting farmers from saving and replanting harvested seed. The farmer may use Roundup Ready seed for one growing season; to use it the following year, the farmer must purchase a new licensed bag.
Mitchell Scruggs and his related farming entities purchased Roundup Ready seed from authorized sellers but never executed the Technology Agreement. Scruggs planted the purchased seed, harvested the crop, and saved and replanted second-generation seed — which still carried the Roundup Ready trait — without obtaining any license from Monsanto. Monsanto sued for patent infringement. The district court granted summary judgment in Monsanto’s favor, and Scruggs appealed, arguing that the original authorized purchase exhausted Monsanto’s patent rights in all subsequent seed derived from that purchase.
The Court’s Holding
The Federal Circuit affirmed, rejecting Scruggs’ exhaustion argument on two independent grounds. First, the court held that exhaustion does not apply to a conditional sale. The authorized seed companies sold the Roundup Ready seed subject to a condition — a prohibition on saving and replanting. Where a sale is conditioned, the patent owner’s rights are not fully exhausted; the buyer obtains only the limited rights the seller was authorized to convey. Because the seed companies sold only the right to use the seed for one growing season, Scruggs received no right to produce subsequent generations.
Second — and more broadly — the court declared the fundamental principle that governs self-replicating biotechnology: “The fact that a patented technology can replicate itself does not give a purchaser the right to use replicated copies of the technology.” Patent exhaustion shields only the specific item sold, not copies or progeny produced by the buyer. Monsanto never sold the second-generation seeds that Scruggs replanted; those seeds were never subject to exhaustion. Even if the original sale had been unconditional, Scruggs would have been free to use only the seed he purchased — not to manufacture additional infringing copies by growing them out.
Key Takeaways
- The patent exhaustion doctrine applies only to the specific article sold by the patentee — not to copies or progeny the buyer produces from that article.
- A conditional sale does not exhaust patent rights; the buyer’s authorized use is limited to the terms of the condition at the time of sale.
- A patented technology’s ability to self-replicate creates no implied license to use replicated copies — this principle covers both biological and potentially digital self-replication scenarios.
- Failing to sign a license agreement (the Technology Agreement) does not create an implied, unrestricted license to use patented seed technology.
- Biotech companies can rely on both patent law and contract law to control downstream use of self-replicating licensed technology.
Why It Matters
Monsanto v. Scruggs reinforced and extended the framework established in the court’s earlier Monsanto v. McFarling (2002) decision, adding the additional holding that even an unconditional sale would not exhaust rights in self-replicating copies. Together, these cases defined the legal foundation for the modern agricultural biotechnology industry’s licensing model.
The decision’s reasoning about self-replicating technology was later unanimously affirmed by the Supreme Court in Bowman v. Monsanto Co. (2013), which held that Vernon Bowman could not escape infringement by planting commodity soybeans that happened to carry the Roundup Ready trait. Scruggs is a critical intermediate precedent in that lineage, showing that the Federal Circuit consistently — and ultimately correctly — predicted how exhaustion doctrine would interact with self-replicating inventions. The principles it articulated may also have implications beyond seeds, wherever digital or biological technologies can be copied or replicated by their users.